The clinical utility of NETest in patients with small intestinal neuroendocrine neoplasms (SI-NENs) – A "real-life" study

#3756

Introduction: Management of patients with SI-NENs is challenging due to biological heterogeneity. Prognostication can be difficult, mostly due to a lack of reliable biomarkers.

Aim(s): To assess the validity of the NETest as a blood biomarker in patients with SI-NENs.

Materials and methods: This single centre prospective study examined 2 cohorts: Patients with metastatic SI-NENs and disease “in-situ”, and “disease-free” patients post-surgery (determined by 68Ga-DOTATATE PET). The NETest result included a value, risk category (normal, low, medium, high) and comment (stable disease, progressive disease). In our primary cohort, primary and secondary outcomes were progression-free survival (PFS) and overall survival (OS) respectively. Cox proportional hazards model was used to perform univariate and multivariate analyses.

Conference:

Presenting Author:

Authors: Gertner J, Hayes A, Furtado O'Mahony L, Glover T, Karia P,

Keywords: Neuroendocrine neoplasm, small intestine, NETest, tumor growth rate, biomarker,